VivoSeq
Psychiatry

Schizophrenia

517

Pipeline Programs↗

100

Active Trials↗

127

Companies Involved↗

Schizophrenia is a highly competitive landscape with 517 programs across 127 companies. The most active players are FORUM Pharmaceuticals Inc, Astellas, Azurity Pharmaceuticals. 125 therapies are approved with 88 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

95/100

Pipeline Velocity

61/100

Mech. Concentration

4/100

Completion Rate

86/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

F

FORUM Pharmaceuticals Inc

3 programs

Phase 1Astellas logo

Astellas

2 programs

Phase 1A

Azurity Pharmaceuticals

2 programs

Phase 1C

Cerevel Therapeutics, LLC

1 program

Phase 1T

Taisho Pharmaceutical Co., Ltd.

1 program

Phase 1S

Sirtsei Pharmaceuticals, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

98%

Small molecule

554 of 568 classified programs — the dominant modality here.

2%ALL OTHERSMonoclonal antibody81%Peptide5<1%Protein / enzyme1<1%

Small molecule leads; the ring shows all 568 classified programs, each share of the total. Modality classified for 99% of 584 pipeline programs.

Analysis

Trial Status

1,123

clinical trials

Completed811 · 72%
Terminated107 · 10%
Unknown status79 · 7%
Recruiting60 · 5%
Not yet recruiting30 · 3%
Withdrawn25 · 2%
Other11 · 1%

Clinical Trials

Trial Activity

1123 trials

Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia
Recruiting·KKing's College London·N/A·NCT06957808·30 enrolled
Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment
Recruiting·—·Phase 2·NCT06881810·98 enrolled
Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia
Recruiting·NNeurosterix·Phase 1·NCT07344948·73 enrolled
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
Recruiting·NNew York State Psychiatric Institute·Phase 4·NCT05208190·280 enrolled
Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia
Recruiting·—·Phase 2·NCT06574360·90 enrolled
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Recruiting·RReviva Pharmaceuticals·Phase 3·NCT05184335·690 enrolled
Sex Differences in NMDA-enhancing Treatment of Schizophrenia
Recruiting·—·Phase 2·NCT07122895·90 enrolled
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
Recruiting·—·Phase 2·NCT04959201·90 enrolled
Anti-Inflammatory Challenge in Schizophrenia
Recruiting·EEmory University·Phase 4·NCT05823532·20 enrolled
Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia
Recruiting·TThe University of Hong Kong·N/A·NCT05169268·10 enrolled
Voice-Based Biomarkers: a Novel Approach to Monitoring and Predicting Schizophrenia Relapses
Recruiting·—·N/A·NCT06613334·200 enrolled
Monotherapy of an NMDA Enhancer for Schizophrenia
Recruiting·—·Phase 2·NCT04745143·80 enrolled
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Recruiting·Neurocrine Biosciences logoNeurocrine Biosciences·Phase 3·NCT07114874·800 enrolled
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
Recruiting·GGedeon Richter Plc.·Phase 3·NCT03817502·330 enrolled
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Recruiting·Neurocrine Biosciences logoNeurocrine Biosciences·Phase 3·NCT07105098·284 enrolled
Page 1 of 75

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)